Exosome Surface Display of IL12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared with Recombinant IL12
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The promise of IL12 as a cancer treatment has yet to be fulfilled with multiple tested approaches being limited by unwanted systemic exposure and unpredictable pharmacology. To address these limitations, we generated exoIL12, a novel, engineered exosome therapeutic that displays functional IL12 on the surface of an exosome. IL12 exosomal surface expression was achieved via fusion to the abundant exosomal surface protein PTGFRN resulting in equivalent potency in vitro to recombinant IL12 (rIL12) as demonstrated by IFNγ production. Following intratumoral injection, exoIL12 exhibited prolonged tumor retention and greater antitumor activity than rIL12. Moreover, exoIL12 was significantly more potent than rIL12 in tumor growth inhibition. In the MC38 model, complete responses were observed in 63% of mice treated with exoIL12; in contrast, rIL12 resulted in 0% complete responses at an equivalent IL12 dose. This correlated with dose-dependent increases in tumor antigen–specific CD8+ T cells. Rechallenge studies of exoIL12 complete responder mice showed no tumor regrowth, and depletion of CD8+ T cells completely abrogated antitumor activity of exoIL12. Following intratumoral administration, exoIL12 exhibited 10-fold higher intratumoral exposure than rIL12 and prolonged IFNγ production up to 48 hours. Retained local pharmacology of exoIL12 was further confirmed using subcutaneous injections in nonhuman primates. This work demonstrates that tumor-restricted pharmacology of exoIL12 results in superior in vivo efficacy and immune memory without systemic IL12 exposure and related toxicity. ExoIL12 is a novel cancer therapeutic candidate that overcomes key limitations of rIL12 and thereby creates a therapeutic window for this potent cytokine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kowal, J., Arras, G., Colombo, M., Jouve, M., Morath, J. P., Primdal-Bengtson, B., Dingli, F., Loew, D., Tkach, M., & Théry, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521230113 · Cited by 3,426 · cited 4×
“In addition, IL12 was confirmed to be on the outside of the exosomes using bead-based pull-down followed by flow cytometry using anti-IL12 and anti-CD81 antibodies (Supplementary Fig.”
BackgroundInfluentialInterleukin 12: still a promising candidate for tumor immunotherapy?
Lasek, W., Zagożdżon, R., & Jakobisiak, M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1523-1 · Cited by 495
Clinical Trials: IL-12 Deaths: Explanation and a Puzzle
Cohen, J. (1995) · Science · doi:10.1126/science.270.5238.908a · Cited by 332 · cited 1×
“However, like the IFNs and IL2 described above, when IL12 is given systemically, patients exhibited substantial toxicity, including flu-like symptoms, lymphopenia, gastrointestinal and hepatic toxicity, and it resulted in two deaths in early dose-escalation trials (13, 14).”
BackgroundSangro, B., Mazzolini, G., Ruiz, J., Herraiz, M., Quiroga, J., Herrero, I., Benito, A., Larrache, J., Pueyo, J., Subtil, J. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.059 · Cited by 320 · cited 1×
“The use of plasmid DNA encoding IL12 (16) or viral delivery of IL12 (18) has shown Codiak BioSciences Inc.”
Cited by
Gupta, D., Zickler, A. M., & El Andaloussi, S. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113961 · Cited by 418
Xu, G., Jin, J., Fu, Z., Wang, G., Lei, X., Xu, J., & Wang, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02312-w · Cited by 269
Kamerkar, S., Leng, C., Burenkova, O., Jang, S. C., McCoy, C., Zhang, K., Dooley, K., Kasera, S., Zi, T., Sisó, S., et al. (2022) · Science Advances · doi:10.1126/sciadv.abj7002 · Cited by 262
Self-citationHarnessing natural killer cells for cancer immunotherapy: dispatching the first responders
Maskalenko, N. A., Zhigarev, D., & Campbell, K. S. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00413-7 · Cited by 256
Liu, Q., Li, D., Pan, X., & Liang, Y. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02081-0 · Cited by 201
“used it to display the singlechain version of human interleukin-12 for cancer therapy [130].”
Background
Metadata
- Authors
- Lewis, N. D., Sia, C. L., Kirwin, K., Haupt, S., Mahimkar, G., Zi, T., Xu, K., Dooley, K., Jang, S. C., Choi, B., Boutin, A., Grube, A., McCoy, C., Sanchez-Salazar, J., Doherty, M., Gaidukov, L., Estes, S., Economides, K. D., Williams, D. E., & Sathyanarayanan, S.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2021-03-01
- Volume
- 20
- Issue
- 3
- Pages
- 523-534
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W3116104321
- Cited by
- 106
- References
- 4
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exosome Surface Display of IL12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared with Recombinant IL12. https://app.cochat.ai/papers/10.1158/1535-7163.mct-20-0484
- The paper
- Lewis, N. D., Sia, C. L., Kirwin, K., Haupt, S., Mahimkar, G., Zi, T., Xu, K., Dooley, K., Jang, S. C., Choi, B., Boutin, A., Grube, A., McCoy, C., Sanchez-Salazar, J., Doherty, M., Gaidukov, L., Estes, S., Economides, K. D., Williams, D. E., & Sathyanarayanan, S. (2021). Exosome Surface Display of IL12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared with Recombinant IL12. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-20-0484
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.